Gamma-Schisandrin inhibits production of amyloid beta-protein 42 in M146L cells.
- Author:
Wei LIU
1
;
Rui YU
;
Jia-Hua WU
;
Huan-Min LUO
Author Information
- Publication Type:Journal Article
- MeSH: Alzheimer Disease; drug therapy; Amyloid Precursor Protein Secretases; antagonists & inhibitors; metabolism; Amyloid beta-Peptides; antagonists & inhibitors; biosynthesis; Animals; CHO Cells; Cricetinae; Cricetulus; Cyclooctanes; Dose-Response Relationship, Drug; Humans; Lignans; Peptide Fragments; antagonists & inhibitors; biosynthesis; Polycyclic Compounds; pharmacology
- From: Acta Pharmaceutica Sinica 2006;41(12):1136-1140
- CountryChina
- Language:Chinese
-
Abstract:
AIMTo investigate the inhibition of amyloid beta-protein 42 (Abeta42) production in M146L cells by gamma-schisandrin.
METHODSM146L cells which can produce considerable Abeta42 in vitro were treated with gamma-schisandrin (1.67, 5.00 and 15.00 microg x mL(-1)), beta-secretase inhibitor (S4562, 100.00 microg x mL(-1)) and gamma-secretase inhibitor (S2188, 13.68 microg x mL(-1)), separately. Cell counting kit-8 (CCK-8) was used to assess cell viability. Enzyme-linked immunosorbent assay (ELISA) was carried out to determine the amount of Abeta42. Western blotting was used to examine C99, an intermediary product of APP cleaved by beta-secretase. beta-Secretase and gamma-secretase activities were assayed by commercial kits.
RESULTSThe CCK-8 assay indicated that different concentrations of gamma-schisandrin had no neurotoxicity on the cultured M146L. And the ELISA test showed that the amount of Abeta42 secreted by M146L cells treated with gamma-schisandrin (5.00 and 15.00 microg x mL(-1)) decreased obviously as compared with solvent control. The results of Western blotting test indicated that there was no change of C99 contents and beta-secretase activity in gamma-schisandrin treated cells, while gamma-secretase activity decreased obviously.
CONCLUSIONgamma-Schisandrin inhibited production of Abeta42 in M146L cells through inhibiting gamma-secretase.
